Brief: Nordic Nanovector, Legochem Biosciences to jointly develop ADCs targeting leukaemias

LigaChem Biosciences

10/10/2016 06:00

Oct 10 (Reuters) - Nordic Nanovector ASA  NANOV.OL : 
    * Says has entered into cooperation with Legochem Biosciences  141080.KQ , South Korea-based 
biopharmaceutical company, to develop novel antibody-drug conjugates (ADCs) targeting leukaemias 
    * Says collaboration supports co's strategy to expand its pipeline of targeted therapies to 
include CD37-targeting antibody products conjugated to anti-cancer compounds that are not 
radionuclides 
 
Source text for Eikon:  ID:nObiW2NfLa  
Further company coverage:  NANOV.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))